Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cell therapies for the sports medicine and severe burn care markets in the United States. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | $292.09M |
| Gross Profit (TTM) | $218.59M |
| EBITDA | $27.90M |
| Operating Margin | -11.80% |
| Return on Equity | 6.59% |
| Return on Assets | 2.17% |
| Revenue/Share (TTM) | $5.78 |
| Book Value | $6.98 |
| Price-to-Book | 6.73 |
| Price-to-Sales (TTM) | 8.21 |
| EV/Revenue | 8.04 |
| EV/EBITDA | 66.94 |
| Quarterly Earnings Growth (YoY) | 18.90% |
| Quarterly Revenue Growth (YoY) | 30.10% |
| Shares Outstanding | $51.07M |
| Float | $50.44M |
| % Insiders | 1.19% |
| % Institutions | 113.89% |
Volatility is currently expanding
BURLINGTON, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16th, 2026.
Vericel NASDAQ: VCEL reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage repair franchise and Burn Care business, as well as expected NexoBrid procurement revenue from a new federal contract.
Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript
Vericel Corporation (VCEL) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.23 per share a year ago.
Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91%
The average of price targets set by Wall Street analysts indicates a potential upside of 53.4% in Vericel (VCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
CAMBRIDGE, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2026 financial results on Thursday, May 7, 2026. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.
